Interim report
Page 1
Regd. Office: E-18, Defence Colony, New Delhi 110024, Ph No.011- 44114411 www.medanta.org, info@medanta.org, CIN: L85110DL2004PLC128319 November 07, 2025 Ref: - GHL/2025-26/EXCH/75 The General Manager Dept. of Corporate Services BSE Limited, P J Towers, Dalal Street, Mumbai - 400 001 Scrip Code: 543654 The Manager Listing Department National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051 Symbol: MEDANTA Sub: Outcome of Board Meeting under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’) Dear Sir(s), We would like to inform you that the Board of Directors of Global Health Limited (‘GHL/Company’) at its meeting held today i.e. Friday, November 07, 2025, has inter alia, approved followings: 1. Unaudited Standalone and Consolidated Financial Results of the Company for the Second Quarter and Half Year ended September 30, 2025 (‘Results’); The certified copies of Results along with Limited Review Reports from the Statutory Auditors M/s Walker Chandiok & Co LLP, Chartered Accountants thereon, are enclosed herewith as Exhibit pursuant to Regulation 33 of the Listing Regulations. 2. Increasing the Beds Capacity of proposed Hospital in Mumbai from existing planned 500 Beds to 750 Beds pursuant to receipt of additional FSI approval from Mumbai Housing and Area Development Authority (MHADA). Details relating to addition of proposed capacity is enclosed as Annexure. Further the Board also approved a cquisition of 30 residential flats in a building currently under construction, close to the proposed Mumbai hospital with an overall investment of upto Rs. 85 Crores primarily for residential accommodation of clinicians and other key staff to be hired. Consequent to above, the total project cost of Mumbai Project stands increased upto Rs. 1530 Crores as against Rs. 1200 Crores earlier. The Trading Window will open after 48 hours from the declaration of above Results, to the Stock Exchanges. The meeting of the Board of Directors commenced at 2.00 P.M. and concluded at 03:55 P.M. Thanking You, For Global Health Limited Rahul Ranjan Company Secretary & Compliance Officer M. No. A17035 Encl: a/a
Page 2
Walker Chandiok &.Co LLP Walker Chandlok & Co LLP • 21st Floor, DLF Square Jacaranda Marg, DLF Phase 11, Gurugram - 122 002 Haryana, India T +91 124 462 8099 F +91 124 462 8001 Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of Global Health Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) To the Board of Directors of Global Health Limited 1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Global Health Limited ('the Company') which includes GHL Employee Welfare Trust ('the Trust') for the quarter ended 30 September 2025 and the year to date results for the period 01 April 2025 to 30 September 2025, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations') . 2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act') , and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. /41w 10,1- /4,-;;:-· - ' Chartered Accoonlanls ( • / \ C: Offices in Ahmedebad, Bengaluru, Chandigarh, Chennai, Oehredun, Goa, Gurugram, Hyderabad, lnd"!1\ Kochi, Ko~ala, W..mbe} New OeR)l, Nolda and Pune \ '· • !.:,_J \ i' ,. ........ ,;., ... '( '· D AC-, ~'v· Walker Chandiok & Co LLP is registered with limited liability with identification number AAC-2085 and has Its registered office at L-41, Connaught Circus, Outer Circle, New Oelhl, 110001, India
Page 3
Walker Chandiok &_Co LLP Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of Global Health Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd) 5. We draw attention to note 6 to the accompanying Statement which describes that a Scheme of Arrangement (the 'Scheme') entered into between the Company and Medanta Holdings Private Limited, an erstwhile wholly owned subsidiary of the Company , has been approved by the National Company Law Tribunal, New Delhi, vide order dated 20 February 2025. As per such Scheme, the subsidiary has been amalgamated with the Company with effect from the appointed date of the Scheme, being 01 April 2024. The aforesaid Scheme has been given accounting effect in the accompanying Statement in accordance with Appendix C to Ind AS 103, Business Combination of Entities Under Common Control, as prescribed in the Scheme, and consequently , comparative financial information of the prior period presented in the Statement have has been restated, the impact of which is further detailed in the said note. Our conclusion is not modified in respect of this matter. For Walker Chandiok & Co LLP Chartered Accountants Firm Registration No: 001076N/N500013 Tarun Gupta Partner Membership No. 507892 UDIN: 25507892BMNSVW1184 Place: Gurugram Date: 07 November 2025
Page 4
SNo . r II Ill rv V VJ VII vrrr rx X xr xrr Global Health Limi ted Rcgis tel'cd Office: Medant a Mediclinic, E-18, Defence Colony, New Delhi • 110024, India Cor porate Office: Medant a-T he Mc dicity , Sector -38 , Gurgaon, Harya na • 122001, Indi a CIN:L85 110DL2004PLC 128319 Tel: +91 124 483 4060; E-mail: compliance@medant a.org; Website: https://www .medanta.ol'g Statement of standalone un audited financi al res ults for the quarter and six month s end ed 30 Septemb el' 2025 (~ in millions, unless othen vise stated) Quarter ended Six months ended Year ended 30 September 2025 30 June 2025 30 Septembel' 2024 30 Se11tember 2025 30 Septembel' 2024 31 March 2025 Particulars Unaudited Unaudited Unaudited Unaudited Unaudited Audited (Restated) (Restated) (Refer note 6) (Refer note 6) Incom e Revenue from operations 9,264.28 8,821.56 8,3 10.49 18,085.84 15.889.11 32,041.46 Other income 228.00 231.39 211.98 459.39 457.37 909.29 Totnl income 9,492.28 9,052.95 8,522.47 18,545.23 16,346.48 32,95 0.75 Expenses Cost of materials consumed 2,032. 16 1,921.63 1,848.08 3,953.79 3,562.65 7,158. 13 Purchases of stock-in-trade (0.44) 25.59 117.83 25. 15 234.74 403.90 Changes in inventories of stock- in-trade 0.52 39.6 1 2. 15 40.13 (3.09) 26.24 Employee benefits expense 2,483.33 2,329.45 1,934. 10 4,812.78 3,758.77 7,462.9 1 Finance costs 88.83 56.58 76.49 145.41 178.30 333.9 1 Depreciation. and amortisation expense 374.28 334.08 382.48 708.36 742.77 1,496. 11 Retainers and consultants fee 1,282.33 1,092.81 1,005.05 2,375. 14 1,960.54 4,038.72 Other expenses 1,540.65 1,466.66 1,403.67 3,007.3 1 2,692.94 5,301.40 Total expenses 7,801.66 7,266.41 6,769.85 15,068.07 13,127.62 26,221.32 Profit before exceptionnl item and tax 1,690.62 1,786.54 1,752.62 3,477.16 3,2 18.86 6,729.43 Exceptional item (refer note 7) (1 59.85) (1 95.92) (355.77) " 498.96 Profit before tax 1,850.47 1,982.46 1,752.62 3,832.93 3,2 18.86 6,230.47 Tax expenses Current tax 358.62 41 3.27 486.08 77 1.89 850.29 1,608 65 Tax pertaining to earlier years " " " " 6.88 Deferred tax charge/(credit) 89.86 49.55 (1 5.26) 139.4 1 1.26 (0.34) Profit after lax I 401.99 I 519.64 I 281.80 2'92 1.63 2 367.31 4 615.28 O ther compt·chcnsive income (i) Items th nt will not be reclassified ID (10.67) 3.01 9.69 (7.66) (16.87) (12.94) statement of profit or loss (ii) JncomcMtax relati ng to items that w ill not 2.69 (0.76) (2.44) 1.93 4.25 3.26 be reclassified to statement of profit or loss Totnl other compr ehen sive income 17.981 2.25 7.25 (5,731 (1 2,621 19.68) Totnl compr ehensive income I 394.01 I 521.89 I 289.05 2 915.90 2 354.69 4 605.60 Paid-up equity share capital (face value of~ 537.58 537.54 537.09 537.58 537.09 537.17 2 each) Reserves (other equity) 34,438.9 1 Earnings per shurc (face value of ~ 2 each) (not annualised for th e c1uarters and six months) Basic(~ per share) 5.22 5.66 4.77 10.87 8.81 17. 18 Diluted (~ l)er share) 5.22 5.65 4.77 10.85 8.81 17. 18 See accompanying notes to the standalone 1111a11ditedjina 11c:ia/ results *
Page 5
Global Health Limited CIN: L851 I0DL2004PLC128319 Note I: Standalone balance sheet as at 30 September 2025 Pa,·ticulars ASSETS Property, plant and equipment Right-of-use assets Capital work-in-progress Intangible assets Intangible assets under development Financial assets Investments Loans Other financial assets Deferred tax assets (net) Income-tax assets (net) Other non-current assets Total non-current assets Current assets Inventories Financial assets Trade receivables Cash and cash equivalents Bank balances other than cash and cash equivalents Loans Other financial assets Other current assets Total current assets Total assets EQUITY AND LIABILITIES Equity Equity share capital Other equity Total equity Liabilities Non-current liabilities Financial liabilities Borrowings Lease liabilities Other financial liabilities Provisions Other non-current liabilities Total non-current liabilities Current liabilities Financial liabilities Borrowings Lease liabilities Trade payables Total outstanding dues of micro enterprises and small enterprises Total outstanding dues of creditors other than micro enterprises and small enterprises Other financial liabilities Other current liabilities Provisions Total current liabilities Total equity and liabilities (fin millions unless otherwise stated) As at 30 September 2025 Unaudited 20,197.34 4,200.12 3,038.03 130.40 2.58 3,670.18 1,464.77 260.01 3.30 591.12 375.32 33,933.17 484.70 3,630.26 7,234.07 4,500.72 170.15 289.19 301.40 16,610.49 50 543.66 537.58 37,409.98 37,947.56 3,140.91 2,068.72 - 701.93 551.72 6,463.28 281.22 209.25 830.87 1,306.33 1,742.21 1,486.20 276.74 6,132.82 so 543.66 * As at 31 Ma,·ch 2025 Audited 14,663.01 3,896.17 4,535.46 48.55 41.71 3,655.08 1,568.59 262.95 140.79 598.61 467.41 29,878.33 489.95 2,915.86 1,900.65 8,627.16 145.87 286.58 161.45 14,527.52 44 405.85 537.17 34,438.91 34,976.08 1, 143.09 1,779.01 477.08 633.26 209.08 4,241.52 261.33 188.46 711.76 975.06 1,145.21 1,470.88 435.55 5,188.25 44 405.85
Page 6
Global Health Limited CIN: L85110DL2004PLCl28319 Note 2: Standalon e Statement of Cas h Flow for the period ended 30 September 2025 (t in millions, unless othenvi se stated) For the period ended For the pe1iod ended Particulars 30 September 2025 30 September 2024 (Restated) Unaudited Unaudited A CASH FLOWS FROM OPERATING ACTIVITIES Profit before tax 3,832.93 3,218.86 Adjustments for: Exceptional items (355.77) - Depreciation and amortisation expense 708.36 742.77 Gain on disposa l of property, plant and equipments (net) (0.33) (6.53) Liabilities written back - (7.82) Government 1,,rants income (3 11 .89) (29.10) Interest income (436 69) (4 15.07) Unrealised foreign exchange loss (net) 6.85 4.27 Finance costs 145.4 1 178.30 Impairment losses on financial assets 40.89 109.21 Employee share based payment expense 171.44 - (Reversal)/provision for contingencies (7.04) 29.54 Operating profit before working capital changes 3,794.16 3,824.43 Movement in working capital: Inventories 5.25 (22.25) Other assets (165.13) (8 1.78) Trade receivables (754.10) (740.90) Other liabilities 142.60 41.72 Trade payables 446.76 122.62 Provisions (90.76) 79.01 Cash flows from operating activities 3,378.78 3,222.85 Income-tax paid (net) (764.40) (653.84) Net cash flows generated from operating activities (A) 2,614.38 2,569.01 Il CASH FLOWS FROM INVESTING ACTIVITIES Purchase of property plant and equipment s, capital work-in-progress and intangible assets (including capital advances, (3,592.55) (2,003.77) capital creditors and deferred payment liabilities) Payment for acquisition of leasehold land (128.7 1) (1,251.1 1) Proceeds from disposal of prope rty, plant and equipments 1.76 14.17 Movement in other bank balances (net) - 4,121.90 623.06 Movement in bank deposits having maturity period more than 12 months (net) 20.2 1 (242.7 1) Interest received 438.27 443.72 Investment in subsidiary compan ies (15.10) (12.50) Investment in equity shares - (26.60) Loan to subsidiaries (250.00) Loans repayment from subsidiaries 79.55 34.43 Net cash flows generated from/ (used in) investing activities (B) 925.33 12 671.31\ C CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from issue of equity share capital (net of share issue expenses) 0.41 0.08 Premium for Employee stock purchase shares to employees of subsidiary companies 18.13 - Proceeds from non-current borrowings 2,006.92 (988.39) Repayment of borrowings - (97.04) Interest paid on borrowings (95.32) (72.79) Payment of interest on lease payments (104.4 1) (99.74) Principal elements of lease liabilities (32.03) (9.11) Net cash flows generated from/ (used in) financing activities (C) 1,793.71 (1,266.99) Net increase/decrease in cash and cash equivalents (A+B+C) 5,333.42 (1,369.29) Cash and cash equivalents at the beginning of the year 1,900.65 3 950.94 Cash and cash equivalents at the end of the period 7,234.07 2,581.65 Reconciliation of cash and cash equivalents as per statement of cash flow Balances with banks in current accounts 408.96 870.05 Cheques on hand 0.14 0.04 Cash on hand 21.37 21.61 Bank deposits with original maturity less than three months 6,803.6 1 1,689.95 7,234.07 2,581.65
Page 7
Global Health Limited Notes to the standalone unaudited financial results (cont'd) : 3 The above standalone financial results of Global Health Limited ('the Company') for the quarter and six months ended on 30 September 2025 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 07 November 2025 and a limited review of the same has been carried out by the statutory auditors. 4 These results have been prepared in accor dance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards specified under Section 133 of the Companies Act 201 3 (the 'Act') read with the Compani es (Indian Accounting Standards) Rules, 20 15 (as amended) and other accounting principles genera lly accepted in India and is in compliance with presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligat ion and Disclos ure Requireme nts) Regulations, 20 15 (as amended). 5 The Chief Operating Decision Maker (CODM) examines the Compa ny's performance from a service perspective and has identified the Healthcar e services as single business segment. 6 The Board of Director s of the Compa ny ("Board") at its meeting held on 21 March 2024, had approved the Scheme of amalgamat ion ("the Scheme") of Medanta Hold ings Private Limited (wholly-owned subsidiary) with the Company, subject to all the necessary statutory / regulatory approva ls. The Scheme had been approved by the Hon'ble National Company Law Tribunal ('NCL T') vide Order dated 20 February 2025 with appointed date being O 1 April 2024. The Scheme became effective on O 1 March 2025 upon filing of the certified true copy of the Order with the Registrar of Compa nies, NCL T of Delhi & Haryana with effect from appointed date. Accord ingly, the Company had accounted for the business comb ination transaction in accordance the account ing treatment prescribed by the Scheme which is consistent with the principl es of Appendix C of Ind AS 103 'Business Combinations under Common Contro l'. Pursuant to above, the comparat ive financial information of the Company in respect of the prior period has been restated as if the aforesaid business combination had occurred from the beginning of the preceding period, irrespective of the actual date of the combination . The impact of the amalgamat ion on the previous period is as under: Particul ars Revenue from operations Profit before tax Profit after tax Earnings per share(~ per share) Particulars Revenue from operation s Profit before tax Profit after tax Earnings per share( ~ per share) Par ticulars Net cash llows from operating activities (A) Net cash used in investing activities (B) Net cash used in fi nancing activities (C) Net decrease in cash and cash equivalents (A+B+C) Cash and cash equivalents at the beginning of the period Cash and cash equivalents at the end of the period As per published financial results for the quarter ended 30 September 2024 6,646.06 1,436.09 1,044.66 3.89 As per publish ed financial results for the six months ended 30 September 2024 12,760.55 2,733.52 2,007 .50 7.47 As per published financial results for the six month s ended 30 September 2024 1,851.14 (2,027.22) (453.4 1) (629.49) 2,186.67 1,557. 18 (fi n millions, unless otherwis e stated) Adjustments on Post amalgamation for the quarter account of ended amalgamation 30 September 2024 (Restated) 1,664.43 8,310.49 316.53 1,752.62 237.14 1,281.80 0.88 4.77 (fin millions, unless othenvise stated) Adjustments on Post amalgamation for the six account of months ended amalgamation 30 Scptcm ber 2024 (Restated) 3, 128.56 15,889.11 485.34 3,2 I 8.86 359.81 2,367.3 1 1.34 8.8 1 (f in millions, unless otherwise stated) Adj ustme nts on Post amalgamation for the six acco unt of months ended amalgamation 30 Septembe r 2024 7 17.87 (644.09) (813.58) (739.80) 1,764.27 1,024.47 (Restated) 2,569.0 1 (2,671.3 1) (1,266 99) (1,369.29) 3,950.94 2,58 1.65
Page 8
Global Healt h Limited Notes to the standalone unaudited financial results (cont'd): 7 Exceptional item for the period ended 30 September 2025 represents: (a) During the quarter ended 30 June 2025, the Company reversed interest liability on Export Promotion Capital Goods (EPCG) amounting to t 195. 92 millions . Pursuant to the filing of merger order with Registrar of Companies (ROC) the EPCG licenses have been transferred from Medanta Holdings Private Limited to the Company . Considering the internal assessme nt done by the Company, the manageme nt is of the view that the required export obli gation will be achieved within the prescribed timeline . (b) During the quarter ended 30 September 2025, the Company reversed stamp duty payable to Government of National Cap ital Territory of Delhi on account of the merger of Medant a Holding s Private Limi ted and the Compa ny, amountin g to t 159.85 million s, pursuant to adjudication of its stamp duty application. 8 During the period ended 30 September 2025: (a) The Company has received in-principl e approval for allotment of land measuring 3.5 acres from Assam Industria l Development Corporation Limited, a Government of Assam undertaking. Subsequent to the period ended 30 September 2025, the Company has received physical possession of land. (b) Noida Hospital and Ranchi Hospital (an additiona l facility in close proximity to the existing facility) of the Compa ny have commenced its operations. 9 During the period ended 30 September 2025, the Boa rd of Directors of the Compa ny has approved the Grant of 605,500 Option s to certain eligible employees and allotted 183,000 shares to GHL Employees Welfare Trust under Part -A and Part- B respectively of Global Health Limited Employees Long-Term Share Based Incentive Plan - 2024 . Em11loyee benefits expense include s: (:i' in millions) Partic ulars Quarter ended Six months ended Year ended 30 Septem her 2025 30 June 2025 30 Septem her 2024 30 Septem her 2025 30 September 2024 31 March 2025 Unaudited Unaudited Unaudited Unaudited Unaudited Audited (Restated) (Refer note 6) Employee share 95.72 75.72 - 171.44 - - based payment expense IO The unaudited standalone financia l results also include the financial informat ion of GHL Employee Welfare Trust . 11 Previous period fi gures have been regrouped /reclassified to conform to the current period's classification . For and on behalf of the Board of Directors of Global Hea lth Limited Place : Gurugram Date : 07 November 2025 Chairman and Managing / ~{ J·,~ ;..r j•/
Page 9
Walker Chandiok &.Co LLP Walker Chandiok & Co LLP 21st Floor, DLF Square Jacaranda Marg, DLF Phase II, Gurugram - 122 002 Haryana, India T +91 124 462 8099 F +91 124 462 8001 Independent Auditor 's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of Global Health Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) To the Board of Directors of Global Health Limited 1. We have reviewed the accompanying statement of consolidated unaudited financial results ('the Statement') of Global Health Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group'), (refer Annexure 1 for the list of subsidiaries included in the Statement) for the quarter ended 30 September 2025 and the consolidated year to date results for the period 01 April 2025 to 30 September 2025, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations'). 2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all signiflcijnt matters that might be identified in an audit. Accordingly, we do not express an audit opinion. ®· ,'-~.~ ~0 7 101-<r 'tr ~ .. r- o_ ":' r' !:._) ~~ Chartered Accounlanls Offices in Ahmedabad, Bengaluru, Chandigarh, Chennai, Dehradun, Goa, Gurugram, Hydorabad, Indore, Kochi, Ko~ala, M.Jmbai, New Delhi, Nolda and Pune Walker Chandiok & Co LLP is registered with limited llablllty with Identification number AAC-2085 and has Its registered office al L-41, Connaught Circus, Outer Circle, New Delhi, 110001, India
Page 10
Walker Chandiok &_Co LLP Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of Global Health Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd) 4. Based on our review conducted, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. For Walker Chandiok & Co LLP Chartered Accountants Firm Registration No: 001076N/N500013 Tarun Gupta Partner Membership No. 507892 UDIN: 25507892BMNSVX6384 Place: Gurugram Date: 07 November 2025
Page 11
Walker Chandiok &.Co LLP Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of Global Health Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd) Annexure-1 List of entities included in the Statement S. No. Name Relationship with the Holding Company 1 Global Health Patliputra Private Limited Wholly owned subsidiary 2 GHL Pharma & Diagnostic Private Limited Wholly owned subsidiary 3 GHL Hospital Limited Subsidiary 4 Global Health Institute of Medical Sciences Wholly owned subsidiary Foundation
Page 12
S. No. I II III IV V VI VII VIII IX X XI Global Henlth Limited Registered Office: Medantn Mediclinic , E-18, Defence Colony, New Delhi - 1 t 0024, India Col'fJorate Office: Mednntn-T he Medicity, Sectot· - 38, Gurgnon, Harynna - 122001, India CIN:L851 I0DL 2004PLC128 31 9 Tel: +91 124 483 4060; E-mail: complianc c@medantn.org; ,v ehsite: https://www.medantn.org Stntcm cnt of consolidated unnuditcd financial results for the qunrtcr nnd six months ended 30 September 2025 lf in millions un less othcnvise stated) Quarter ended Sii: months ended Year ended Pnrticulnrs 30 September 2025 30 .June 2025 30 Sept em her 2024 30 Septem her 2025 30 September 2024 31 March 2025 Unnudited Unaudited Unaudited Unaudited Unaudited Audited Income Revenue from operations 10,992.22 10,308.37 9.565.55 2 1,300.59 18, 176.32 36,923. 15 Other income 197.26 204.57 182. 16 401.83 401.43 790.97 Total income 11,189.48 10,512.94 9,747.71 21,702.42 18,577.75 37,714. 12 Expenses Cost of materials consumed 2,266.92 2,130.77 2,042.75 4,397 .69 3,9 18.80 7,899.6 0 Purchases of stock-in-trade 287.84 3 17.90 28 1.54 605.74 512.51 924.61 Changes in inventories of stock-in-trade 0.80 (58. 10) (44.47) (57.30) (62.85) (27.52) Employee benefi ts expense 2,743.34 2,564 .04 2,142.86 5,307.38 4, 154.7 1 8,245.42 Finance costs 17 1.12 137.85 159.75 308.97 339.54 652.59 Depreciation and amortisation expense 497.26 45 1.08 494.30 948.34 960.48 1,937.48 Retainers and consultants foe 1,549.45 1,367.0 0 1,223.29 2,9 16.45 2,408.08 4,973 .43 Other expenses I 834.46 I 716.9 1 I 636.70 3 551.37 3 098.97 6 136.98 Total expenses 9,351.19 8,627.45 7,936.72 17,978.64 15,330.24 30 742.59 Profit befo re exceptional item and tax 1,838.29 1,885.49 1,810.99 3,723.78 3,247.51 6,971.53 Exceptional item (refer note 6) (1 59.85\ 11 95.92\ . (355.77) . 498.96 Profit before t11 x 1,998.14 2,081.41 1,810.99 4,079.55 3,247.51 6,472.57 Tax expenses Current tax 358 .62 4 13.27 486.08 77 1.89 850.29 1,608.65 Tax pertaining to earlier years . . . . 6.88 DefctTed tax charge 55.52 78.32 16.73 133.84 26.40 43.86 Profit 11fter tax I 584.00 I 589.82 1 308.1 8 3 173.82 2 370.82 4 813.18 Other comprehensive income (i) Items that will not be reclassified to statement (12.34) 3. 11 10.07 (9.23) (17.03) (9. 13) of profil or loss (ii) Income-tax relating to items that will not be 3.1 1 (0.78) (2.59) 2.33 4.24 2.43 reclassified to statement of profit or loss Totul other comprehensive income (9.23 2.33 7.48 (6.90) '1 2.79) (6.70) Totnl comprehensive income 1,574.77 1,592.15 1,315.66 3,1 66.92 2,358.03 4,806.48 Profit after tax attributable to: (i) Owners oftl1e Holding Company 1,584.4 1 1,590.09 1,308.44 3, 174.50 2,371.3 0 4,8 14.37 (i i) Non-controlling interests (0.4 1) (0.27) (0.26) ro.6Sl (0.48) (1.19) Other comprehensive income attributable to: (i) Owners of the Holding Company (9.23) 2.33 7.48 (6.90) ( 12.79) (6.70) (ii) Non-controlling interests . . . . . Total compreh ensive Incom e att ributab le to: (i) Owners of the Holding Compnny 1,575. 18 1,592.42 1,315.92 3, 167.60 2,358.5 1 4,807.67 (ii) Non-controll ing interests (0.4 1) (0.271 (0.261 (0.68) (0.48) ( 1.19) Paid-up equity share capital (face value oft 2 537.58 537.54 537.09 537.58 537.09 537.17 each) Reserves ( other equity) 33,326 .93 Earnings per sha.re (face value of , 2 each) (not annualised for the quarters and six months) Basic (t per share) 5.89 5.92 4.87 I 1.8 1 8.83 17.92 Diluted (t uer share) 5.89 5.9 1 4.87 11.79 8.83 17.92 See accompanymg notes to the conso/ulaled 1ma11d1ted ji11a11cwl re,\'/1/Js *
Page 13
Global Health Limited CIN:L85110DL2004PLC128319 Note 1: Consolidated balance sheet as at 30 September 2025 Particulars ASSETS Non-c111Tent assets Property, plant and equipment Right-of-use assets Capital work-in-progress Intangible assets Intangible assets under development Financial assets Investments Other financial assets Deferred tax assets (net) Income-tax assets (net) Other non-current assets Total non-current assets Current assets Inventories Financial assets Tracie receivables Cash and cash equivalents Bank balances other than cash and cash equivalents Other financial assets Other current assets Total current assets Total assets EQUITY AND LIABILITIES Equity Equity share capital Other equity Non-controlling interests Total equity Liabilities Non-current liabilities Financial liabilities Borrowings Lease liabilities Other financial liabilities Provisions Other non-current liabilities Total non-current liabilities Current liabilities Financial liabilities Borrowings Lease liabilities Trade payables Total outstandin g clues of micro enterprises and small enterprises Total outstandin g dues of creditors other than micro enterprises and small enterprises Other financial liabilities Other current liabilities Provisions Total current liabilitie s Total equity and liabilities (tin millions, unless otherwise stated) As at 30 September 2025 Unaudited 26,240.56 5,595.29 3,175.17 153.88 4.03 27.10 286.18 198.72 732.16 396.56 36,809.65 732.58 3,650.97 7,591.84 4,609.81 344.75 355.86 17,285.81 54,095.46 537.58 36,538.95 25.30 37,101.83 4,546.92 3,938.56 4.12 734.37 563.13 9,787.10 720.39 243 06 976.94 1,530.55 1,884.3 1 1,534.05 317.23 7,206.53 54,095.46 As at 31 March 2025 Audited 19,752.64 5,322.74 5,285.21 64.69 48.16 27.10 300.48 330.23 687.18 512.64 32,331.07 671.41 2,918.56 2,302.00 8,921.35 327.98 189.93 15,331.23 47,662 .30 537.17 33,326.93 10.97 33,875.07 2,641.00 3,594.06 481.16 661.68 221.16 7,599.06 637.83 304.43 793.65 I, 154.47 1,3 11.97 1,511.84 473.98 6,188.17 47,662.30 0 e,ill/1 < . '- / ((} -0 0 0 *
Page 14
Global Health Limited CIN:L85110DL2004PLC128319 Note 2: Consolidated statement of cash flow for the period ended 30 September 2025 Particulnrs A CASH FLOWS FROM OPERA TING ACTIVITIES Profit before tax Adjustments for: Exceptional items Depreciation and amortisation expense Gain on sale of property, plant and equipments (net) Gain on de-recognition of lease liabilities and right of use assets Liabilities written back Government grants income Interest income Unrealised foreign exchange loss (net) Finance costs Impairment losses on financial assets Employee share based payment expense (Reversal)/provision for contingencies Operating profit before working capital changes Movement in working capital : Inventories Other assets Trade receivables Other liabilities Trade payables Provisions Cash flows from operating activities Income-tax paid (net) Net cnsh flows generated from opernting activities (A) B CASH FLOWS FROM INVESTING ACTIV ITIES Purchase of property, plant and equipments, capital work-in-progress and intangible assets (including capital advances, capital creditors and deferred payment liabilities) Payment for acquisition of leasehold land Proceeds from disposal of property , plant and equipments Movement in other bank balances (net) Movement in bank deposits having maturity period more than 12 months (net) Interest received Investment in equity shares Net cash flows generated from/ (used in) investing activities (B) C CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from issue of equity share capital Proceeds from issue of equity share capital to non-controlling interest Proceeds from non-current borrowings Repayme nt of borrowings Interest paid on borrowings Payment of interest on lease payments Principal elements of lease liabilities Net cnsh flows generutcd from/ (used in) financing activities (C) Net increase/decrease in cash and cash equivalents (A+B+C) Cash and cash equivalents at the beginning of the year Cash and cash equivalents at the end of the period Reconciliation of cash anrl cash equivalents as per statement of cash flow Balances with banks in current accounts Cheques on hand Cash on hand Bank deposits with original maturity less than three months ......-:-;:rin7 -c\ ,, ,r1 ~<j ) --- -,.:__!' ") ,~- ·...: * (' (fin millions unle ss otherwise stated) For the period ended For the pe1-iod ended 30 September 2025 30 September 2024 Unaud ited Unaudited 4,079.55 3,247.5 1 (355.77) - 948.34 960.48 (0.33) (6.52) (1.81) - - (7.83) (312.48) (29.69) (377.93) (360.54) 16.08 3.88 308.97 339.54 40. 14 109.95 178.81 - (7.04) 29.54 4,516.53 4,286.32 (61.17) (88.99) (205.03) (103.19) (771.29) (764.41) 153.60 60.86 555.77 210.61 (86.25) 86.73 4,102.16 3,687.93 (816.87) (695.23) 3 285.29 2 992.70 (4,127.11) (2,643.54) (128.71) (1 ,25 1.11) 2.51 14.17 4,307 .05 644.74 3 1.83 (2 16.07) 379.05 389.27 - (2660) 464.62 (3 089.14) 0.4 1 0.08 15.00 12.50 2,006.79 341 .65 (49.55) ( I, 139.5 1) (173.78) (143.15) (194.72) (208.49) (64.22) (15.05) I 539.93 (1151.97) 5,289.84 (1,248.41) 2,302.00 4,246.08 7 591.84 2 997.67 463.37 1,279.34 0.14 0.08 30.40 28.23 7,097.93 1,690.02 7 591.84 2 997.67
Page 15
Global Health Limited Notes to the consolidated unaudited financial results (cont'd): 3 The above consolidated financial results of Global Health Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiar ies together referred to as 'the Group') for the quarter and six months ended 30 September 2025 have been reviewed by the Aud it Committee and approved by the Board of Directors at their respective meetings held on 07 November 2025 and a limited review of the same has been carried out by the statutory auditors. 4 These results have been prepared in accordance with the recognition and measurement princip les laid down in the applicable Indian Accounting Standards specified under Section 133 of the Companies Act 2013 (the 'Act') read with the Compan ies (Indian Account ing Standards) Rules , 2015 (as amended) and other accounting principles generally accepted in India and is in compl iance with presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations , 2015 (as amended) . 5 The Chief Operating Decision Maker (CODM) examines the Group's performance from a service perspective and has identified the Healthcare services as sing le business segme nt. 6 Except ional item for the period ended 30 September 2025 represents: (a) During the quarter ended 30 June 2025, the Holding Company reversed interest liability on Export Promotion Capita l Goods (EPCG) amounting to t 195.92 millions . Pursuant to the filing of merger order with Registrar of Companies (ROC) the EPCG licenses have been transferred from Medanta Holdings Private Limited to the Holding Company. Consider ing the internal assessment done by the Holding Company, the management is of the view that the required export obligation will be achieved within the prescribed timeline. (b) During the quarter ended 30 Septe mber 2025, the Holding Company reversed stamp duty payable to Government of National Capital Territory of Delhi on account of the merger ofMedanta Holding Private Limited and the Holding Company, amounting tot 159.85 millions, pursuant to adjudication of its stamp duty application. 7 During the period ended 30 September 2025: (a) The Holding Company has received in-principle approval for allotment of land measuring 3.5 acres from Assam Industrial Development Corporation Limited , a Government of Assam undertaking . Subsequent to the period ended 30 September 2025 , the Holding Company has received physical possession of land. (b) Noida Hospital and Ranchi Hospital (an addit ional facility in close proximity to the existing facility) of the Holding Company have commenced its operations . 8 During the period ended 30 September 2025, the Board of Directors of the Holding Company has approved the Grant of 605,500 Options to certa in eligible emp loyees and allotted 183,000 shares to GHL Employees Welfare Trust under Part -A and Part- B respec tively of GHL L TLP 2024 Plan. Employee benefits expense includes: (~ in millions, unless otherwise stated) Quarter ended Six months ended Year ended Particulars 30 September 2025 30 June 2025 30 Sept em bcr 2024 30 September 2025 30 Sept em bcr 2024 31 March 2025 Unaudited Unaudited Unaudited Unaudited Uuaudited Audited Employee share 100.04 78.77 - 178.81 - - based payment expense 9 Previous period figures have been regrouped/reclassified to conform to the current period's classification . Place : Gurugram Date : 07 November 2025 For and on behalf' of the Board of Di recto l's of Global Health Limited DI'. Naresh Tre~ Chail'man and Managing Directol'
Page 16
Regd. Office: E-18, Defence Colony, New Delhi 110024, Ph No.011- 44114411 www.medanta.org, info@medanta.org, CIN: L85110DL2004PLC128319 Disclosure pursuant to Regulation 30 of SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 Annexure Sr. No. Particulars Details 1. Existing Capacity The current approved bed capacity of upcoming Mumbai hospital was planned at 500 beds 2. Existing Capacity Utilization Currently, Medan ta Hospital at Mumbai is under construction 3. Proposed Capacity Addition 250 beds addition. Total Beds = 750 4. Period within which the proposed capacity is to be added 3 to 4 years from the date of commencement of construction post approvals 5. Investment Required Total project cost of Mumbai Project including cost of Land / FSI purchase and cost of purchase of 30 residential flats stand increased to Rs. 1530 Crores as against Rs. 1200 Crores intimated earlier 6. Mode of Financing Funded by a combination of internal accruals and debt financing 7. Rationale Upon receipt of additional FSI approval from Mumbai Housing and Area Development Authority (MHADA), the allowable build up area has increased enabling an increase in planned bed capacity from 500 beds to 750 beds